1
Lymphomas
November 2015
This bulletin covers aspects of lymphomas and should be of interest to multidisciplinary teams working in
this area.
Sections can include:
 Combined Modality Therapies
 Drug & Biological Therapies
 Pathology, Staging, Polymorphisms & Biomarkers
 Prognosis, Survival & Risk Factors
 Radiotherapy & Imaging
 Stem Cell Transplantation
 Supportive Care & Symptom Management
Many of the following articles are available online via the NHS Scotland Knowledge Network.
Please use the links where provided and your ATHENS password. A complete list of available
online journals and registration for ATHENS can be found at www.knowledge.scot.nhs.uk/
If the article you require is not available via the NHS Scotland Knowledge Network and you would
like to request a print copy, please submit your request online at www.quest.scot.nhs.uk
This bulletin contains a selection of material gathered from a search of the evidence base, and is not
intended to be comprehensive. Professional judgment should be exercised when appraising the material.
The Library takes no responsibility for the wording, content and accuracy of the information supplied,
which has been extracted in good faith from reputable sources. NHSGGC is not responsible for the
content of external internet sites.
Compiled by:
Kirsty Coltart
Subject Librarian
Beatson West of Scotland Cancer Centre
0141 301 7285, kirsty.coltart@ggc.scot.nhs.uk
1
2
General
Ansell, S.M. (2015). Hodgkin Lymphoma: Diagnosis and Treatment. Mayo Clinic proceedings
90,11:1574-1583.
Ansell, S.M. (2015). Non-Hodgkin Lymphoma: Diagnosis and Treatment. Mayo Clinic proceedings
90,8:1152-1163.
British Committee for Standards in Haematology Guidelines for the investigation and
management of nodular lymphocyte predominant Hodgkin lymphoma. (October 2015)
Casulo C, Day B, Dawson KL, et al. (2015). Disease characteristics, treatment patterns, and
outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the
National Lymphocare Study+. Annals of Oncology 26,11:2311-2317.
ESMO Clinical Practice Guidelines: Diffuse large B-cell lymphoma (DLBCL). (Sep 2015)
ESMO Clinical Practice Guidelines: Peripheral T-cell lymphomas. (Sep 2015)
Hottinger AF, Alentorn A and Hoang-Xuan K. (2015). Recent developments and controversies in
primary central nervous system lymphoma. Current opinion in oncology 27,6:496-501.
Kirkegaard MM, Coupland SE, Prause JU, et al. (2015). Malignant lymphoma of the conjunctiva.
Survey of ophthalmology 60,5:444-458.
Nakamura S and Matsumoto T. (2015). Treatment Strategy for Gastric Mucosa-Associated Lymphoid
Tissue Lymphoma. Gastroenterology clinics of North America 44,3:649-660.
Sadot E, Yahalom J, Do RK, et al. (2015). Clinical features and outcome of primary pancreatic
lymphoma. Annals of Surgical Oncology 22,4:1176-1184.
Stathis A and Younes A. (2015). The new therapeutical scenario of Hodgkin lymphoma. Annals of
Oncology 26,10:2026-2033.
Vargo JA, Gill BS, Balasubramani GK, et al. (2015). What is the optimal management of early-stage
low-grade follicular lymphoma in the modern era?. Cancer 121,18:3325-3334.
Wagner-Johnston ND, Link BK, Byrtek M, et al. (2015). Outcomes of transformed follicular lymphoma
in the modern era: a report from the National LymphoCare Study (NLCS). Blood 126,7:851-857.
Combined Modality Therapies
Bi XW, Xia Y, Zhang WW, et al. (2015). Radiotherapy and PGEMOX/GELOX regimen improved
prognosis in elderly patients with early-stage extranodal NK/T-cell lymphoma. Annals of
Hematology 94,9:1525-1533.
Brockelmann PJ and Engert A. (2015). The GHSG Approach to Treating Hodgkin's Lymphoma.
Current Hematologic Malignancy Reports 10,3:256-265.
2
3
Chen R, Palmer JM, Martin P, et al. (2015). Results of a Multicenter Phase II Trial of Brentuximab
Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory
Hodgkin Lymphoma. Biology of Blood & Marrow Transplantation 21,12:2136-2140.
Chen YB, Li S, Fisher DC, et al. (2015). Phase II Trial of Tandem High-Dose Chemotherapy with
Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell
Transplantation for Patients with High-Risk Lymphoma. Biology of Blood & Marrow Transplantation
21,9:1583-1588.
Cieri N, Di Bartolo O and Corradini P. (2015). Rituximab for indolent lymphomas before and after
allogeneic hematopoietic stem cell transplantation. Current opinion in hematology 22,6:469-475.
Damaj G, Ivanoff S, Coso D, et al. (2015). Concomitant systemic and central nervous system nonHodgkin lymphoma: the role of consolidation in terms of high dose therapy and autologous stem
cell transplantation. A 60-case retrospective study from LYSA and the LOC network.
Haematologica 100,9:1199-1206.
Graf SA, Stevenson PA, Holmberg LA, et al. (2015). Maintenance rituximab after autologous stem cell
transplantation in patients with mantle cell lymphoma. Annals of Oncology 26,11:2323-2328.
Kanakry JA, Gocke CD, Bolanos-Meade J, et al. (2015). Phase II Study of Nonmyeloablative
Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation
Rituximab and Donor Selection Based First on Non-HLA Factors. Biology of Blood & Marrow
Transplantation 21,12:2115-2122.
Kuruvilla J, MacDonald DA, Kouroukis CT, et al. (2015). Salvage chemotherapy and autologous stem
cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12.
Blood 126,6:733-738.
Michot JM, Mazeron R, Danu A, et al. (2015). Concurrent Etoposide, Steroid, High-dose Ara-C and
Platinum chemotherapy with radiation therapy in localised extranodal natural killer (NK)/T-cell
lymphoma, nasal type. European journal of cancer 51,16:2386-2395.
Witzig TE, Hong F, Micallef IN, et al. (2015). A phase II trial of RCHOP followed by
radioimmunotherapy for early stage (stages I/II) diffuse large B-cell non-Hodgkin lymphoma:
ECOG3402. British journal of haematology 170,5:679-686.
Drug & Biological Therapies
Avivi I and Goy A. (2015). Refining the Mantle Cell Lymphoma Paradigm: Impact of Novel Therapies
on Current Practice. Clinical Cancer Research 21,17:3853-3861.
Becker M, Tschechne B, Reeb M, et al. (2015). Bendamustine as first-line treatment in patients with
advanced indolent non-Hodgkin lymphoma and mantle cell lymphoma in German routine clinical
practice. Annals of Hematology 94,9:1553-1558.
Casulo C, Byrtek M, Dawson KL, et al. (2015). Early Relapse of Follicular Lymphoma After Rituximab
Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk
for Death: An Analysis From the National LymphoCare Study. Journal of Clinical Oncology
33,23:2516-2522.
3
4
Chihara D, Pro B, Loghavi S, et al. (2015). Phase II study of HCVIDD/MA in patients with newly
diagnosed peripheral T-cell lymphoma. British journal of haematology 171,4:509-516.
Czuczman MS, Goy A, Lamonica D, et al. (2015). Phase II study of bendamustine combined with
rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings.
Annals of Hematology 94,12:2025-2032.
Dawson, K. (2015). Rituximab Faster Infusion for Patients With Non-Hodgkin's Lymphoma in the
United States: Implications for Nursing Practice. Journal of Infusion Nursing 38,Suppl 6:S4-S10.
Fayad L, Ansell SM, Advani R, et al. (2015). Dacetuzumab plus rituximab, ifosfamide, carboplatin
and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after
rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, doubleblind, placebo-controlled phase 2b trial. Leukemia & lymphoma 56,9:2569-2578.
Goy A, Kalayoglu Besisik S, Drach J, et al. (2015). Longer-term follow-up and outcome by tumour cell
proliferation rate (Ki-67) in patients with relapsed/refractory mantle cell lymphoma treated with
lenalidomide on MCL-001(EMERGE) pivotal trial. British journal of haematology 170,4:496-503.
Haverkamp H, Boll B, Eichenauer DA, et al. (2015). Impact of Bleomycin and Vincristine Dose
Reductions in Patients With Advanced Hodgkin Lymphoma Treated With BEACOPP: An Analysis
of the German Hodgkin Study Group HD12 and HD15 Trials. Journal of Clinical Oncology 33,22:24302436.
Hess G, Keller U, Scholz CW, et al. (2015). Safety and efficacy of Temsirolimus in combination with
Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma. Leukemia 29,8:16951701.
Howlett C, Snedecor SJ, Landsburg DJ, et al. (2015). Front-line, dose-escalated
immunochemotherapy is associated with a significant progression-free survival advantage in
patients with double-hit lymphomas: a systematic review and meta-analysis. British journal of
haematology 170,4:504-514.
Illidge T, Klein C, Sehn LH, et al. (2015). Obinutuzumab in hematologic malignancies: Lessons
learned to date. Cancer treatment reviews 41,9:784-792.
Iyer SP and Foss FF. (2015). Romidepsin for the Treatment of Peripheral T-Cell Lymphoma.
Oncologist 20,9:1084-1091.
Kiesewetter B, Ferreri AJ and Raderer M. (2015). Chemoimmunotherapy for Mucosa-Associated
Lymphoid Tissue-Type Lymphoma: A Review of the Literature. Oncologist 20,8:915-925.
Kimby E, Ostenstad B, Brown P, et al. (2015). Two courses of four weekly infusions of rituximab with
or without interferon-alpha2a: final results from a randomized phase III study in symptomatic
indolent B-cell lymphomas. Leukemia & lymphoma 56,9:2598-2607.
Leonard JP, Jung SH, Johnson J, et al. (2015). Randomized Trial of Lenalidomide Alone Versus
Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401
(Alliance). Journal of Clinical Oncology 33,31:3635-3640.
Mocikova H, Pytlik R, Stepankova P, et al. (2015). Can Rituximab Improve the Outcome of Patients
with Nodular Lymphocyte-Predominant Hodgkin's Lymphoma?. Acta Haematologica 134,3:187-192.
4
5
O'Connor OA, Horwitz S, Masszi T, et al. (2015). Belinostat in Patients With Relapsed or Refractory
Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study. Journal of
Clinical Oncology 33,23:2492-2499.
Park BB, Kim WS, Suh C, et al. (2015). Salvage chemotherapy of gemcitabine, dexamethasone, and
cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium
for improving survival of lymphoma (CISL) trial. Annals of Hematology 94,11:1845-1851.
Perez-Callejo D, Gonzalez-Rincon J, Sanchez A, et al. (2015). Action and resistance of monoclonal
CD20 antibodies therapy in B-cell Non-Hodgkin Lymphomas. Cancer treatment reviews 41,8:680689.
Ruan J, Martin P, Shah B, et al. (2015). Lenalidomide plus Rituximab as Initial Treatment for MantleCell Lymphoma. New England Journal of Medicine 373,19:1835-1844.
Sarkozy C and Coiffier B. (2015). Primary refractory diffuse large B cell lymphoma in the rituximab
era. Current opinion in oncology 27,5:377-383.
Sehn LH, Goy A, Offner FC, et al. (2015). Randomized Phase II Trial Comparing Obinutuzumab
(GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin
Lymphoma: Final Analysis of the GAUSS Study. Journal of Clinical Oncology 33,30:3467-3474.
Wang ML, Blum KA, Martin P, et al. (2015). Long-term follow-up of MCL patients treated with singleagent ibrutinib: updated safety and efficacy results. Blood 126,6:739-745.
Wilson WH, Young RM, Schmitz R, et al. (2015). Targeting B cell receptor signaling with ibrutinib in
diffuse large B cell lymphoma. Nature medicine 21,8:922-926.
Wudhikarn K, Smith BJ, Button AM, et al. (2015). Relationships between chemotherapy,
chemotherapy dose intensity and outcomes of follicular lymphoma in the immunochemotherapy
era: a report from the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research
Excellence Molecular Epidemiology Resource. Leukemia & lymphoma 56,8:2365-2372.
Yildirim M, Kaya V, Demirpence O, et al. (2015). The role of gender in patients with diffuse large B
cell lymphoma treated with rituximab-containing regimens: a meta-analysis. Archives of Medical
Science 11,4:708-714.
Zhang SQ, Smith SM, Zhang SY, et al. (2015). Mechanisms of ibrutinib resistance in chronic
lymphocytic leukaemia and non-Hodgkin lymphoma. British journal of haematology 170,4:445-456.
Pathology, Staging, Polymorphisms & Biomarkers
Brockelmann PJ, Goergen H, Fuchs M, et al. (2015). Impact of centralized diagnostic review on
quality of initial staging in Hodgkin lymphoma: experience of the German Hodgkin Study Group.
British journal of haematology 171,4:547-556.
Carbone A, Gloghini A, Castagna L, et al. (2015). Primary refractory and early-relapsed Hodgkin's
lymphoma: strategies for therapeutic targeting based on the tumour microenvironment. Journal of
Pathology 237,1:4-13.
5
6
Glaser SL, Clarke CA, Keegan TH, et al. (2015). Time Trends in Rates of Hodgkin Lymphoma
Histologic Subtypes: True Incidence Changes or Evolving Diagnostic Practice?. Cancer
Epidemiology, Biomarkers & Prevention 24,10:1474-1488.
Healey R, Naugler C, de Koning L, et al. (2015). A classification tree approach for improving the
utilization of flow cytometry testing of blood specimens for B-cell non-Hodgkin
lymphoproliferative disorders. Leukemia & lymphoma 56,9:2619-2624.
Ho C and Rodig SJ. (2015). Immunohistochemical markers in lymphoid malignancies: Protein
correlates of molecular alterations. Seminars in diagnostic pathology 32,5:381-391.
Krem MM, Press OW, Horwitz MS, et al. (2015). Mechanisms and clinical applications of
chromosomal instability in lymphoid malignancy. British journal of haematology 171,1:13-28.
Matsuki E and Younes A. (2015). Lymphomagenesis in Hodgkin lymphoma. Seminars in cancer
biology 34,14-21.
Ng DP, Wu D, Wood BL, et al. (2015). Computer-aided detection of rare tumor populations in flow
cytometry: an example with classic Hodgkin lymphoma. American Journal of Clinical Pathology
144,3:517-524.
O'Malley DP, Auerbach A and Weiss LM. (2015). Practical Applications in Immunohistochemistry:
Evaluation of Diffuse Large B-Cell Lymphoma and Related Large B-Cell Lymphomas. Archives of
Pathology & Laboratory Medicine 139,9:1094-1107.
Pina-Oviedo S, Weissferdt A, Kalhor N, et al. (2015). Primary Pulmonary Lymphomas. Advances in
Anatomic Pathology 22,6:355-375.
Prognosis, Survival & Risk Factors
Compaci G, Rueter M, Lamy S, et al. (2015). Ambulatory Medical Assistance - After Cancer (AMAAC): A model for an early trajectory survivorship survey of lymphoma patients treated with
anthracycline-based chemotherapy. BMC Cancer 15,781.
Eichenauer DA, Plutschow A, Fuchs M, et al. (2015). Long-Term Course of Patients With Stage IA
Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the German Hodgkin
Study Group. Journal of Clinical Oncology 33,26:2857-2862.
Gang AO, Pedersen M, d'Amore F, et al. (2015). A clinically based prognostic index for diffuse large
B-cell lymphoma with a cut-off at 70 years of age significantly improves prognostic stratification:
population-based analysis from the Danish Lymphoma Registry. Leukemia & lymphoma 56,9:25562562.
Haverkos B, Tyler K, Gru AA, et al. (2015). Primary Cutaneous B-Cell Lymphoma: Management and
Patterns of Recurrence at the Multimodality Cutaneous Lymphoma Clinic of The Ohio State
University. Oncologist 20,10:1161-1166.
Pastore A, Jurinovic V, Kridel R, et al. (2015). Integration of gene mutations in risk prognostication
for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective
analysis of a prospective clinical trial and validation in a population-based registry. Lancet
Oncology 16,9:1111-1122.
6
7
Radiotherapy & Imaging
American College of Radiology ACR appropriateness criteria: Diffuse Large B-Cell Lymphoma.
(October 2015)
American College of Radiology ACR appropriateness criteria: Hodgkin Lymphoma-Unfavorable
Clinical Stage I and II. (October 2015)
El-Galaly TC, Pedersen MB, Hutchings M, et al. (2015). Utility of interim and end-of-treatment PET/CT
in peripheral T-cell lymphomas: A review of 124 patients. American Journal of Hematology
90,11:975-980.
Eng T and Ha CS. (2015). Image-guided radiation therapy in lymphoma management. Radiation
Oncology Journal 33,3:161-171.
Keraliya AR, Krajewski KM, Giardino AA, et al. (2015). Imaging of Nervous System Involvement in
Hematologic Malignancies: What Radiologists Need to Know. AJR.American Journal of
Roentgenology 205,3:604-617.
Mamot C, Klingbiel D, Hitz F, et al. (2015). Final Results of a Prospective Evaluation of the Predictive
Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma
Treated With R-CHOP-14 (SAKK 38/07). Journal of Clinical Oncology 33,23:2523-2529.
Mendes F, Domingues C, Teixo R, et al. (2015). The importance of radiotherapy on diffuse large B
cell lymphoma treatment: a current review. Cancer & Metastasis Reviews 34,3:511-525.
Ruskone-Fourmestraux A, Matysiak-Budnik T, Fabiani B, et al. (2015). Exclusive moderate-dose
radiotherapy in gastric marginal zone B-cell MALT lymphoma: Results of a prospective study with
a long term follow-up. Radiotherapy & Oncology 117,1:178-182.
Sachsman S, Flampouri S, Li Z, et al. (2015). Proton therapy in the management of non-Hodgkin
lymphoma. Leukemia & lymphoma 56,9:2608-2612.
Ulaner GA, Goldman DA, Sauter CS, et al. (2015). Prognostic Value of FDG PET/CT before
Allogeneic and Autologous Stem Cell Transplantation for Aggressive Lymphoma. Radiology
277,2:518-526.
Special Populations
Arico M, Mussolin L, Carraro E, et al. (2015). Non-Hodgkin lymphoma in children with an associated
inherited condition: A retrospective analysis of the Associazione Italiana Ematologia Oncologia
Pediatrica (AIEOP). Pediatric Blood & Cancer 62,10:1782-1789.
Linabery AM, Erhardt EB, Richardson MR, et al. (2015). Family history of cancer and risk of pediatric
and adolescent Hodgkin lymphoma: A Children's Oncology Group study. International Journal of
Cancer 137,9:2163-2174.
Mauz-Korholz C, Metzger ML, Kelly KM, et al. (2015). Pediatric Hodgkin Lymphoma. Journal of Clinical
Oncology 33,27:2975-2985.
7
8
Minard-Colin V, Brugieres L, Reiter A, et al. (2015). Non-Hodgkin Lymphoma in Children and
Adolescents: Progress Through Effective Collaboration, Current Knowledge, and Challenges
Ahead. Journal of Clinical Oncology 33,27:2963-2974.
Supportive Care & Symptom Management
Spector DJ, Noonan D, Mayer DK, et al. (2015). Are lifestyle behavioral factors associated with
health-related quality of life in long-term survivors of non-Hodgkin lymphoma?. Cancer
121,18:3343-3351.
Surgery
Bairey O, Shvidel L, Perry C, et al. (2015). Characteristics of primary splenic diffuse large B-cell
lymphoma and role of splenectomy in improving survival. Cancer 121,17:2909-2916.
British Committee for Standards in Haematology Guidelines on the Identification and Management
of Pre‐Operative Anaemia. (September 2015)
Transplantation
Epperla N, Fenske TS, Hari PN, et al. (2015). Recent advances in post autologous transplantation
maintenance therapies in B-cell non-Hodgkin lymphomas. World Journal of Transplantation 5,3:8188.
Epperla N, Fenske TS, Lazarus HM, et al. (2015). Post-autologous transplant maintenance therapies
in lymphoid malignancies: are we there yet? Bone marrow transplantation 50,11:1393-1404.
Hartmann T, Hubel K, Monsef I, et al. (2015). Additional plerixafor to granulocyte colony-stimulating
factors for haematopoietic stem cell mobilisation for autologous transplantation in people with
malignant lymphoma or multiple myeloma. Cochrane Database of Systematic Reviews 10,010615.
Marchesi F, Pimpinelli F, Gumenyuk S, et al. (2015). Cytomegalovirus reactivation after autologous
stem cell transplantation in myeloma and lymphoma patients: A single-center study. World Journal
of Transplantation 5,3:129-136.
Rahemtulla A and Terpos E. (2015). Hodgkin's lymphoma (relapsed or refractory): autologous stem
cell therapy. Clinical Evidence 2015
Tonorezos ES, Stillwell EE, Calloway JJ, et al. (2015). Arrhythmias in the setting of hematopoietic cell
transplants. Bone marrow transplantation 50,9:1212-1216.
8
9
Please note that the journal articles you are accessing are subject to the terms and conditions imposed
by the publisher, so there will be a limit on the number of articles an individual may download or print from
a single issue of a journal. You can consult your local NHSGGC library with any queries.
If you have any questions regarding this or any other library services please contact Library staff –
contact details are at the beginning of the bulletin.
Sources used for this bulletin:
OVID MEDLINE, SIGN, NICE and Healthcare Improvement Scotland
9